NASDAQ · Biotechnology · USD
Replimune Group, Inc. (REPL) Stock Analysis
Replimune Group, Inc. (REPL) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.
Last Updated: October 21, 2026
Price History
No price data available
Hover for the daily close. The dotted line marks the period open.
REPL Key Statistics
As of Oct 21, 2026Trading
- Open
- $11.37
- Previous Close
- $11.42
- Day's Range
- 11.37–12.05
- 52-Week Range
- 1.50–16.33
- Volume
- 2.20M
- BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
- 0.94
Valuation
- Market Cap
- $1.10B
- P/E Ratio
- unprofitable
- EPS (ttm)Profit attributable to each share over the last twelve months.
- −3.15
Financials (FY)
- Revenue (FY)
- $0.00
- Net Income (FY)
- −$313.94M
- Shares Outstanding
- 94.22M
- 1-Year Return
- +44.69%
Dividend and dates
- Earnings Date
- November 5, 2026estimated
- Avg Volume
- 3.96M
Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.
Key facts
As of October 21, 2026, REPL closed at $11.72, +44.69% over 1 year.
Replimune Group, Inc. (REPL) has a market capitalization of $1.10B.
In fiscal 2025, REPL reported revenue of $0.00.
REPL Stock Return by Calendar Year
Replimune Group, Inc. (REPL) return since Jul 2018: what $10,000 became
- 1 year
- $10,000 $14,469
- +44.69%
- 5 years
- $10,000 $4,050
- −59.50%
- Since Jul 2018
- $10,000 $7,731
- −22.69%
If you had invested $10,000 in Replimune Group, Inc. (REPL) at the close on July 20, 2018, the earliest close on record here, it would have been worth $7,731 at the close on October 21, 2026: −22.69% in total, −3.07% a year, over a partial period shorter than 10 years. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.
Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.
| Year | Return |
|---|---|
| 2026 (partial year) | +20.58% |
| 2025 | −19.74% |
| 2024 | +43.65% |
| 2023 | −69.01% |
| 2022 | +0.37% |
| 2021 | −28.96% |
| 2020 | +165.85% |
| 2019 | +43.50% |
| 2018 (partial year) | −34.04% |
As of October 21, 2026.
REPL Revenue and Earnings by Fiscal Year
FY ends March| Fiscal year | Revenue | Net income | Net margin |
|---|---|---|---|
| 2025 | $0.00 | −$313.94M | — |
| 2024 | $0.00 | −$247.30M | — |
| 2023 | $0.00 | −$215.79M | — |
| 2022 | $0.00 | −$174.28M | — |
| Fiscal year | Revenue | Gross profit | Operating income | Net income | Net margin |
|---|---|---|---|---|---|
| 2025 | $0.00 | — | −$318.32M | −$313.94M | — |
| 2024 | $0.00 | — | −$259.85M | −$247.30M | — |
| 2023 | $0.00 | — | −$232.85M | −$215.79M | — |
| 2022 | $0.00 | — | −$174.17M | −$174.28M | — |
Annual figures as reported, in the company's reporting currency. As of March 31, 2026.
Recent News
Replimune Group (REPL) Stock Looks Rich After A 141% Run
YahooReplimune Group: A Hold Until TUDRIQEV's Commercial Potential Becomes Clear
SeekingAlphaReplimune Group (REPL) Launches TUDRIQEV As Its Valuation Story Comes Into Focus
YahooReplimune Announces TUDRIQEV™ Now Available in the U.S. for Advanced Melanoma
YahooReplimune Group Announces Commercial Availability Of TUDRIQEV In U.S. To Treat Unresectable Advanced Cutaneous Melanoma
BenzingaReplimune Says Stockholders Approved Amendment To Increase Authorized Common Shares From 150M To 300M, Effective September 15
Benzinga
All 20 articles ↓Show fewer ↑
Replimune Group, Inc. (REPL) Shareholder/Analyst Call Prepared Remarks Transcript
SeekingAlphaReplimune to Present at the Cantor Global Healthcare Conference 2026
YahooJP Morgan Maintains Overweight on Replimune Group, Raises Price Target to $21
BenzingaReplimune Group Files Shelf Prospectus For Offering; Size Not Disclosed
BenzingaReplimune Group Q1 EPS $(0.72) Beats $(0.73) Estimate
BenzingaReplimune Prices ~$150M Underwritten Offering Of 9,701,490 Shares And Warrants At $12.06 Per Unit
BenzingaWedbush Upgrades Replimune Group to Outperform, Raises Price Target to $19
BenzingaReplimune Group, Inc. (REPL) Shareholder/Analyst Call Transcript
SeekingAlphaTwo Rejections, Messy Process: Replimune Finally Secures FDA Approval for Skin Cancer Treatment
BenzingaReplimune Group, Inc. (REPL) Shareholder/Analyst Call - Slideshow
SeekingAlphaReplimune Receives FDA Accelerated Approval For TUDRIQEVTM In Combination With Nivolumab For Treatment Of Adults With Unresectable Advanced Cutaneous Melanoma
BenzingaLeerink Partners Upgrades Replimune Group to Outperform, Raises Price Target to $17
BenzingaReplimune Skin Cancer Therapy Hopes Revive After Positive FDA Panel Vote
BenzingaWedbush Maintains Neutral on Replimune Group, Raises Price Target to $12
Benzinga
News provided by third-party sources. Not financial advice.
Analysis
Data-derivedEvery figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.
Related Biotechnology Stocks
Vertex Pharmaceuticals Incorporated
$132.95B
MRNAModerna, Inc.
$98.14B
REGNRegeneron Pharmaceuticals, Inc.
$82.95B
ARGXargenx SE
$55.97B
ONCBeOne Medicines AG
$43.97B
RVMDRevolution Medicines, Inc.
$41.64B
Popular Healthcare Stocks
Eli Lilly and Company
$1.13T
JNJJohnson & Johnson
$621.22B
ABBVAbbVie Inc.
$503.27B
UNHUnitedHealth Group Incorporated
$374.30B
MRKMerck & Co., Inc.
$369.78B